In advance of Phase 2 trials, preclinical data showed the potential efficacy of Namodenoson (CF102) from Israel’s Can-Fite (see Jan 2012).  It inhibited the growth and proliferation of liver fibrosis cells, supporting its potential ability to combat non-alcoholic fatty liver disease.

http://ir.canfite.com/press-releases/detail/776/new-preclinical-data-show-can-fites-namodenoson-cf102-inhibits-liver-fibrosis—-supports-potential-efficacy-in-treatment-of-nash